Biodesix Revenue and Competitors
Estimated Revenue & Valuation
- Biodesix's estimated annual revenue is currently $52.5M per year.
- Biodesix received $5.3M in venture funding in May 2018.
- Biodesix's estimated revenue per employee is $193,750
- Biodesix's total funding is $239.7M.
- Biodesix has 271 Employees.
- Biodesix grew their employee count by 23% last year.
Biodesix Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Biodesix?
We are a molecular diagnostics company at the forefront of innovation in oncology. We discover, develop and deliver blood-based diagnostics to answer unmet clinical questions across the continuum of lung disease and improve the standard of care for patients. We see both sides of lung cancer with our Biodesix Lung Reflex® testing strategy by integrating the GeneStrat® genomic test and the VeriStrat® proteomic test. Results within 72-hours can inform a comprehensive treatment strategy and expedite time to treatment. This is the fastest turnaround time for testing of this type, which can reduce a patient's time from diagnosis to starting treatment. In addition to our on-market products, we collaborate with biopharma to help optimize their clinical development programs with blood-based diagnostics. By using cutting edge techniques in machine learning alongside our comprehensive multi-omic approach, looking at biomarkers in both the tumor and host, our service offering helps partners develop, commercialize and find optimal combinations of novel therapeutics. Our established product development process and quality systems support diagnostic development up to and including companion diagnostic commercialization. All clinical and biopharma service testing is performed in our best-in-class diagnostic laboratory, certified by CAP, CLIA, CLEP and ISO 13485.keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals
Number of Employees
Employee Growth %
BOULDER, Colo.--(BUSINESS WIRE)--Mar 9, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the fourth quarter and year ended December 31, 2020 after the close of tradin ...
Boulder-based lung cancer diagnostic company Biodesix announced Tuesday that it has entered into an agreement with Thermo Fisher Scientific to bring a blood-based DNA sequencing analysis for liquid biopsies to the general public. Unlike traditional biopsies, which require a surgery to obtain a ...
Boulder-based Biodesix, Inc. is acquiring a Kansas lab run by Oncimmune Holdings, a global immunodiagnostics group, and is partnering with it to help commercialize its lung nodule malignancy risk test in the United States as part of an agreement valued at up to $28 million over the next five yea ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|2014-01-13||$20.0M||Undisclosed||Capital Royalty Partners LP||Article|